Johnson & Johnson Reports Positive Results For Talvey With Darzalex Faspro In Treating R/R MM

Johnson & Johnson (JNJ) announced positive results from its Phase 3 MonumenTAL-3 trial evaluating Talvey in combination with Darzalex Faspro, with or without pomalidomide, for the treatment of patients with relapsed/refractory Multiple Myeloma.